Serum Opsonins to Serogroup B Meningococci in Meningococcal Disease
- 1 January 1989
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 21 (3) , 267-276
- https://doi.org/10.3109/00365548909035696
Abstract
The opsonic activity to serogroup B meningococci (B: 15:P1.16) was measured in sera from 101 patients with meningococcal disease using a chemiluminescence method. On admission to hospital the opsonic activity was lower in 12 patients who died than in survivors (p=0.0007). A close association was observed between the opsonic activity and the duration of symptoms before admission, the severity of the disease, and the levels of IgG antibodies to the outer membrane complex (15: P1.16). The opsonic activity was low in 2 premorbid sera compared to healthy controls. The mean opsook activity peaked 2 weeks after admission and was still high 3–5 years later. Meningococcal strains of different serogroups, serotypes and subtypes induced a similar increase in opsonic activity to B:15:P1.16 meningococci. No increase in activity was observed in sera from patients with meningitis and septicemia caused by other bacteria. Serum opsonins seem to be of significant importance in the host defence against serogroup B meningococci.This publication has 31 references indexed in Scilit:
- Killing of Neisseria meningitidis by Human Neutrophils: Implications for Normal and Complement-Deficient IndividualsThe Journal of Infectious Diseases, 1987
- Epidemic Meningococcal Disease: Synthesis of a Hypothetical Immunoepidemiologic ModelClinical Infectious Diseases, 1982
- Disseminated Intravascular Coagulation, Antithrombin III, and Complement in Meningococcal InfectionsActa Medica Scandinavica, 1981
- Antibody-dependent Mononuclear Cell-mediated Antimeningococcal ActivityJournal of Clinical Investigation, 1980
- Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.The Journal of Experimental Medicine, 1978
- Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of AgeNew England Journal of Medicine, 1977
- SPREAD OF MENINGOCOCCAL INFECTION WITHIN HOUSEHOLDSThe Lancet, 1974
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969